Clinical Trials

We are evaluating the safety and efficacy of LB-102 for schizophrenia in multiple clinical trials.

Ongoing Phase 2 Clinical Trial of LB-102:

We are currently conducting a Phase 2 clinical trial to test LB-102 in patients with acute schizophrenia. This trial (NCT06179108) aims to evaluate the efficacy and safety of LB-102. Here’s what you need to know:

Trial Details

The trial involves patients who have shown clinical response to previous antipsychotic treatments (except clozapine) in the prior 12 months. It is a double-blind, randomized, placebo-controlled trial, meaning neither the patients nor the researchers know who is receiving LB-102 or a placebo.

Dosing

Patients will start with a seven-day period to clear previous medications from their system. They will then receive daily doses of LB-102 (50 mg, 75 mg, or 100 mg) or a placebo for four weeks. We are testing different doses to find the most effective and safest option.

Goals

The main goal is to see how well LB-102 works compared to the placebo by measuring changes in schizophrenia symptoms using the PANSS (Positive and Negative Syndrome Scale) score over four weeks.

Want to learn more about LB Pharma?

CONNECT NOW